Home›Stock Screener›Lasa Supergenerics›Financial Statements

Lasa Supergenerics Complete Financial Statements

11 Years of Data
2026 - 2016

In FYNone, Lasa Supergenerics (LASA) reported revenue ₹7 Cr, net profit ₹-17 Cr and EPS ₹-3.30, with a net profit margin of -140.0% and ROE of -41.7%. Full financial statements from FY2016 to FY2026 (11 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see LASA share price screener.

Complete Financial Data Export

Profitability Ratios

Net Profit Margin -140.00% 2026 data
EBITDA Margin -112.00% 2026 data
Operating Margin -113.00% 2026 data
Return on Assets -34.31% 2026 data
Return on Equity -41.67% 2026 data

Balance Sheet Ratios

Current Ratio 33.00 2026 data
Equity Ratio 82.35% 2026 data
Asset Turnover 0.25 2026 data

LASA Revenue, Net Profit & EBITDA — Year-on-Year Growth

LASA YoY (March 2026 vs Period) — revenue -72.0%, net profit +51.4%, EBITDA +67.9%, expenses -70.4%.

Revenue Growth
-72.0%
Year-over-Year
Net Profit Growth
+51.4%
Year-over-Year
EBITDA Growth
+67.9%
Year-over-Year
Expense Growth
-70.4%
Year-over-Year
Assets Growth
-32.5%
Year-over-Year
Equity Growth
-13.4%
Year-over-Year
Operating Cash Flow Growth
-250.0%
Year-over-Year
Financing Cash Flow Growth
-200.0%
Year-over-Year

LASA Income Statement — Revenue, EBITDA & Net Profit

Lasa Supergenerics revenue ₹7 Cr, EBITDA ₹-9 Cr, net profit ₹-17 Cr, EPS ₹-3.30 (None) — net profit margin -140.0%. Compare with Lasa Supergenerics value estimation to assess whether the stock is under or overvalued.

Periods ₹ Crores
Particulars None March 2026 March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016
Revenue 7 25 148 104 131 137 202 168 170 247 201 0
Expenses 16 54 136 102 136 121 155 137 159 202 153 0
EBITDA -9 -28 11 2 -5 16 47 30 12 45 48 0
Operating Profit Margin % 417.00% -113.00% 4.00% 2.00% -5.00% 12.00% 23.00% 18.00% 7.00% 17.00% 23.00% 0.00%
Depreciation 6 6 12 11 13 15 16 17 19 18 8 0
Interest 0 0 3 2 4 0 2 8 8 11 12 0
Profit Before Tax -16 -35 -19 -19 -42 -6 30 5 -16 15 2 0
Tax 0 0 -5 3 -4 -1 7 1 -4 3 0 0
Net Profit -17 -35 -15 -22 -39 -5 23 4 -12 12 2 0
Earnings Per Share (₹) -3.30 -6.80 -2.95 -4.34 -7.71 -1.06 5.60 0.89 -5.26 5.43 1.15 0.00

LASA Balance Sheet — Assets, Liabilities & Shareholders' Equity

LASA total assets ₹102 Cr, total equity ₹84 Cr, total liabilities ₹ Cr (2025) — ROE -41.7%.

Years Annual Data ₹ Crores
Particulars 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016
ASSETS
Total Assets 102 151 164 209 208 232 259 287 228 0
Current Assets 33 38 39 66 64 76 86 109 79 0
Fixed Assets 68 110 119 137 143 152 162 170 119 0
Capital Work in Progress 0 3 5 5 0 0 7 7 30 0
Investments 0 0 0 0 0 0 0 0 0 0
Other Assets 33 39 40 67 65 80 90 110 80 0
LIABILITIES
Total Liabilities
Current Liabilities 1 5 3 7 8 15 46 62 83 0
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 84 97 118 158 159 142 105 117 76 0
Share Capital 50 50 50 50 41 41 23 23 0 0
Reserves & Surplus 32 47 68 108 118 101 82 95 75 0

LASA Cash Flow Statement — Operating, Investing & Financing

Lasa Supergenerics operating cash flow ₹-3 Cr, investing ₹8 Cr, financing ₹-6 Cr, net cash flow ₹0 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016
Operating Activities -3 2 -17 9 41 14 41 40 -3 0
Investing Activities 8 0 11 -3 -4 -2 -7 -44 0 0
Financing Activities -6 -2 -4 0 -36 -10 -33 4 0 0
Net Cash Flow 0 0 -10 6 1 2 0 0 -3 0